Roche Holding (RHHBY)
(Delayed Data from OTC)
$40.40 USD
-0.21 (-0.52%)
Updated Oct 31, 2025 04:00 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RHHBY 40.40 -0.21(-0.52%)
Will RHHBY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for RHHBY
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Other News for RHHBY
Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window
VYMI: Foreign 4.3% Dividend Yield Made Cheap And Simple
FDA moves to accelerate biosimilar development, lower drug costs
FDA moves to accelerate biosimilar development, lower drug costs
Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback